BDCA2 stimulators(C-Type lectin domain family 4 member C stimulants), HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), MSLN modulators(Mesothelin modulators)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Celldex Therapeutics, Inc.

Active Organization-

Inactive Organization

Celldex Therapeutics, Inc.

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with CDX-1402

100 Translational Medicine associated with CDX-1402

100 Patents (Medical) associated with CDX-1402

Literatures (Medical) associated with CDX-1402

01 Jul 2017·Cancer Research

Abstract 3664: CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors

Author: Ramakrishna, Venky ; Keler, Tibor ; Mills-Chen, Laura ; Vitale, Laura ; Sisson, Crystal ; Goldstein, Joel ; He, Li-Zhen ; Testa, James ; Marsh, Henry ; Wasiuk, Anna ; Zhao, Biwei ; Weidlick, Jeff ; Widger, Jenifer

AbstractThe use of mAbs to target antigens to the endocytic receptor Dec205 on dendritic cells (DC) is an effective means to elicit helper and cytolytic T cell responses in the presence of appropriate adjuvants to activate DC. We have translated this concept to clinical studies using a fully human Dec205-specific mAb genetically altered to include the entire NY-ESO-1 cancer antigen (CDX-1401), which when combined with TLR agonists results in effective stimulation of both cellular and humoral NY-ESO-1-specific responses in cancer patients (Dhodapkar MV et al., Sci. Transl. Med. 6:232-251, 2014). Building on this concept, we developed a new fusion protein in which the Dec205 mAb is engineered to carry two tumor-related antigens in tandem [ECDs of mesothelin (MSLN) and HER2]. HER2 and MSLN are broadly expressed in selected tumor types and provide an expanded opportunity for this immunotherapy approach. We previously generated an anti-mouse DC-targeted HER2 vaccine (αDec205-HER2) and a MSLN vaccine (αDec205-MSLN) and demonstrated in mouse studies that they were potent in eliciting strong and broad CD4 T cell immunity, cross priming of CD8 T cells and humoral responses specific for HER2 or MSLN antigens, respectively. In this work we tested the impact of expressing two tumor antigens in the same construct on the immune responses to each antigen. Mice of various genetic backgrounds were immunized with equimolar amount of αDec205-HER2 (6.8 μg), αDec205-MSLN (5 μg) or αDec205-MSLN-HER2 (8.3 μg) in combination with poly IC-LC plus anti-CD40 or anti-CD27 as adjuvant. Similar levels of CD4 and CD8 T cell responses upon single or dual antigen vaccination were observed in the assessment of intracellular cytokines and IFNγ-ELISPOT after ex vivo stimulation with peptide pools derived from either HER2 or MSLN. High titers of anti-HER2 and anti-MSLN IgG, including IgG1 and IgG2a, were elicited upon αDec205-MSLN-HER2 vaccination. Both humoral and cellular responses were boosted by multiple dosing of the vaccine. Based on these data we developed CDX-1402 using our anti-human Dec205 mAb genetically fused to MSLN and HER2. CDX-1402 was shown to effectively deliver these antigens to human DC in vitro for activation of antigen-specific T cells. In vitro stimulation of healthy volunteer circulating T cells with autologous DC treated with CDX-1402 plus TLR agonist resulted in T cell cultures that produced IFNγ only when presented with CDX-1402-treated DCs or DC loaded with a select panel of HLA-I/II synthetic peptides derived from either MSLN or HER2 but not with control peptides. We also observed that T cells sensitized to CDX-1402 recognize cancer cell lines that express the vaccine antigen and HLA. Altogether, the data lend support for the use of CDX-1402 as a novel immunotherapeutic for treatment of multiple cancer types expressing MSLN and/or HER2.Citation Format: Li-Zhen He, Jenifer Widger, James Testa, Laura Mills-Chen, Biwei Zhao, Jeff Weidlick, Crystal Sisson, Anna Wasiuk, Laura Vitale, Joel Goldstein, Henry Marsh, Tibor Keler, Venky Ramakrishna. CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3664. doi:10.1158/1538-7445.AM2017-3664

100 Deals associated with CDX-1402

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	United States	Celldex Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CDX-1402

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation